Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 36.40 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 77.37 | Oscillator | Neutral |
| Williams %R (14) | -38.53 | Oscillator | Neutral |
| MACD (12, 26, 9) | -1.24 (Hist 0.35) | Oscillator | Buy |
| Average Directional Index (14) | 47.93 (+DI 16.1 / -DI 37.3) | Trend | Strong Sell |
| EMA 20 | 20.68 | MA | Strong Sell |
| SMA 20 | 19.81 | MA | Sell |
| EMA 50 | 22.91 | MA | Strong Sell |
| SMA 50 | 24.64 | MA | Strong Sell |
| SMA 200 | 23.84 | MA | Strong Sell |
Current price $19.73
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 19, 26 | Needham | maintain | Buy | Buy |
| Oct 13, 26 | UBS | downgrade | Buy | Neutral |
| Oct 8, 26 | RBC Capital | maintain | Outperform | Outperform |
| Sep 25, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Sep 25, 26 | Needham | maintain | Buy | Buy |
| Sep 25, 26 | BMO Capital | maintain | Outperform | Outperform |
| Sep 25, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 25, 26 | Deutsche Bank | maintain | Buy | Buy |
| Sep 24, 26 | Needham | maintain | Buy | Buy |
FY2018 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 6, 26 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | M-Exempt | 14,292 @ $17.84 | $255.0K |
| Aug 6, 26 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | S-Sale | 5,000 @ $29.00 | $145.0K |
| Aug 5, 26 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | M-Exempt | 5,849 @ $17.84 | $104.3K |
| Aug 5, 26 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | M-Exempt | 5,849 @ $17.84 | $104.3K |
| Aug 6, 26 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | S-Sale | 9,292 @ $29.34 | $272.6K |
| Aug 5, 26 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | S-Sale | 5,849 @ $29.00 | $169.6K |
| Aug 6, 26 | Schneyer Mark C. | officer: EVP, CHIEF FINANCIAL OFFICER | M-Exempt | 14,292 @ $17.84 | $255.0K |
| Jul 29, 26 | Thompson Elizabeth H.Z. | officer: EVP, Head of Research & Dev | M-Exempt | 32,272 | — |
| SC 13G | Aug 7, 2026 | 2026-08-07 08:21:15 | View |
| 144 | Aug 5, 2026 | 2026-08-05 20:49:44 | View |
| 10-Q | Aug 5, 2026 | 2026-08-04 18:12:40 | View |
| 8-K | Aug 4, 2026 | 2026-08-04 16:16:35 | View |
| 4 | Jul 31, 2026 | 2026-07-31 18:00:17 | View |
| 4 | Jun 29, 2026 | 2026-06-29 18:00:05 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ACAD | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 8.8x | -18.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 31.7x | EPS est. 0.62 | Elevated |
| Price / Book | 2.6x | 6.6x | Discount |
| Price / Sales | 3.0x | 5.4x | Discount |
| EV / EBITDA | 26.6x | -17.4x | Discount |
| Return on equity | 32.4% | — | Top tier |
| Gross margin | 91.1% | 94.2% | In line |
| Debt / Equity | 0.06 | 0.10 | Conservative |
| Piotroski / Altman Z | 4/9 | Z 4.69 | Safe zone |
Discounted cash flow model
Stock news · updated daily
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Needham and Company LLC in a research note issued on Monday, Benzinga reports. They currently have a $35.00 target price on the biopharmaceutical company's stock. Needham and Company LLC's target price would suggest a potential upside of 78.52%
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
C4 Therapeutics (NASDAQ: CCCC - Get Free Report) and ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Volatility and Risk C4 Therapeutics has a beta
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 0.07 | 0.18 | Beat 164.1% | $308.0M |
| May 6, 2026 | 0.04 | 0.02 | Miss -50.0% | $268.1M |
| Feb 25, 2026 | 0.14 | 1.60 | Beat 1067.9% | $284.0M |
| Nov 5, 2025 | 0.14 | 0.42 | Beat 200.0% | $278.6M |
| Aug 6, 2025 | 0.14 | 0.16 | Beat 14.3% | $264.6M |
| May 7, 2025 | 0.10 | 0.11 | Beat 10.0% | $244.3M |